Genus - Directorate Appointment
For Immediate Release 29 June 2020
('Genus', or the 'Company')
Appointment of Non-Executive Director and Chairman Designate
Iain brings extensive Board and governance experience relevant to Genus, as well as strong commercial, science and agribusiness expertise across a range of industries, with a particular focus on consumer goods and food. Iain is currently Chairman of
Iain's appointment follows an extensive search process using an external search agency.
Commenting on the appointment, Lesley Knox, the Company's Senior Independent Director who led the planned succession process, said, "For over a decade, Bob Lawson has led the successful transformation of Genus to become a world leader in the provision of elite bovine and porcine genetics and related services. I am delighted that Iain has agreed to join Genus and transition into the Chairman role. I believe that Iain brings the right mix of Board experience, international exposure and business skills to maintain the continued growth of the Company and its seamless execution on strategy. The transition period prior to the AGM will enable Iain to gain a strong understanding of the Company's business before becoming the Chairman in November."
Iain Ferguson added, "I am delighted to have been appointed as a Director and Chairman-designate of Genus. I look forward to working with the Chairman, Bob Lawson, the Board, the executive committee and the rest of the Genus team on the opportunities ahead for this great Company."
Bob Lawson, Chairman of Genus, commented "Genus is an outstanding company and one that I have been extremely proud to have worked for. I look forward to assisting Iain in understanding the Company's operations and wish him every success as he sets out to lead Genus through the next stage of our growth."
Tel: +44(0)1256 345970
Bob Lawson, Chairman
Stephen Wilson, Chief Executive
Tel: +44(0)207 466 5000
Charles Ryland /
This announcement is available on the Genus website www.genusplc.com
Genus is a world-leading animal genetics company. Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.
Genus's worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chains.
The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.
With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison,
Details of any payments to be made to Iain Ferguson will be disclosed in full in the Company's 2020 Directors' Remuneration Report. Any such terms will be consistent with the Company's approved Directors' Remuneration Policy.
This announcement is made in accordance with Listing Rule 9.6.11R. There are no matters to be disclosed in connection with Listing Rule 9.6.13R (2) - (6). The person responsible for making this announcement on behalf of the Group is Dan Hartley (General Counsel and Company Secretary).
This information is provided by RNS, the news service of the
Quick facts: Genus plc
Market Cap: £2.24 billion
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE